Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
22 studies found for:    Gd-DOTA
Show Display Options
Rank Status Study
1 Recruiting Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)
Conditions: Renal Insufficiency, Chronic;   Kidney Diseases
Interventions: Drug: Calcium EDTA;   Drug: Gd-DOTA
2 Not yet recruiting Evaluation of Gadoterate in Patients With Decreased Kidney Function
Condition: Renal Dysfunction
Interventions: Drug: Gadoterate;   Other: No Gadoterate
3 Recruiting Assessment of Immediate Adverse Reactions From Dotarem in Children Under 2 Years of Age
Conditions: Adverse Reaction to Drug;   Allergic Reaction to Contrast Media
Intervention: Drug: Gadoteric Acid
4 Completed Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.
Condition: Neoplastic CNS Lesions
Interventions: Drug: Gadovist® (Gadobutrol, BAY86-4875);   Drug: Dotarem
5 Active, not recruiting DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC
Condition: Hepatocellular Carcinoma
Intervention: Drug: Meglumine Gadoterate
6 Completed Suprasacral Parallel Shift - Ultrasound/MR Image Fusion Guided Lumbosacral Plexus Block
Conditions: Hip Fractures;   Anesthesia Local;   Pain, Perioperative
Intervention: Drug: Lidocaine-epinephrine added gadoterate meglumine
7 Completed Shamrock - Ultrasound/MR Image Fusion Guided Lumbar Plexus Block
Conditions: Hip Fractures;   Anesthesia, Local;   Pain, Postoperative
Interventions: Procedure: Ultrasound/MR image fusion guided lumbar plexus block (Shamrock);   Procedure: Ultrasound guided lumbar plexus block (Shamrock);   Drug: Lidocaine-epinephrine added gadoterate meglumine
8 Not yet recruiting A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts
Condition: Autoimmune Diseases
Interventions: Radiation: 18F-FDG PET/CT Imaging;   Radiation: 11C-MET PET/CT Imaging;   Procedure: MRI Imaging with intravenous contrast with gadoterate meglumine;   Procedure: Minor Salivary gland (labial) biopsy
9 Completed Eovist vs. Dotarem Healthy Volunteer MRI
Condition: Transient Severe Arterial Phase Motion
Interventions: Drug: gadoxetate disodium;   Drug: gadoterate dimeglumine;   Drug: Saline
10 Completed
Has Results
Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions
Conditions: Diagnostic Self Evaluation;   Central Nervous System Diseases
Interventions: Drug: Dotarem (gadoterate meglumine);   Drug: Magnevist (gadopentetate dimeglumine)
11 Completed
Has Results
Renal Safety Evaluation After Dotarem®-Enhanced MRI
Condition: Renal Insufficiency
Interventions: Drug: Dotarem®-enhanced MRI;   Other: non-enhanced MRI
12 Completed
Has Results
Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease
Condition: Peripheral Arterial Disease
Interventions: Drug: Dotarem;   Drug: Gadovist
13 Not yet recruiting Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI
Condition: Brain Diseases
Intervention: Drug: Dotarem
14 Completed DOTAREM Pharmacokinetics and Safety Study in Pediatric Subjects Aged < 2 Years
Condition: Magnetic Resonance Imaging
Intervention: Drug: DOTAREM
15 Completed
Has Results
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
Condition: Cerebral Arterial Diseases
Interventions: Drug: Dotarem;   Other: TOF MRA
16 Completed
Has Results
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
Condition: Cerebral Arterial Diseases
Interventions: Drug: Dotarem;   Other: TOF MRA
17 Terminated
Has Results
Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)
Condition: Renal Disease
Interventions: Drug: Dotarem;   Other: Time of Flight
18 Completed Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients
Conditions: Breast Cancer Female;   Doxorubicin Induced Cardiomyopathy
Interventions: Drug: Doxorubicin;   Device: Achieva, Philips Medical Systems (3T magnet);   Drug: Gadoterate Meglumine
19 Completed
Has Results
Safety and Dialysability of Dotarem® in Dialysed Patients
Condition: End-stage Renal Failure
Intervention: Drug: Dotarem® IV injection at 0.1 mmol/kg
20 Terminated
Has Results
Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
Condition: Renal Artery Stenosis
Interventions: Drug: Gadoterate meglumine (Dotarem);   Other: Time of Flight Magnetic Resonance Angiography

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.